It’s high-time to re-evaluate the value of induced-chemotherapy for reinforcing immunotherapy in colorectal cancer

Frontiers in Immunology

Immunology

Yuejun Han¹  Ketao Jin¹  Mengxiang Yang¹  Shiya Yao¹  Huanrong Lan² 

[1] Department of Colorectal Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang, China;Department of Surgical Oncology, Hangzhou Cancer Hospital, Hangzhou, Zhejiang, China;

关键词: colorectal cancer;    immunotherapy;    inducing chemotherapy;    immunogenic cell death;    combination therapy;    clinical trial;    tumor microenvironment;   

DOI  :  10.3389/fimmu.2023.1241208

 received in 2023-06-16, accepted in 2023-10-09,  发布年份 2023

来源: Frontiers

【 摘 要 】

Immunotherapy has made significant advances in the treatment of colorectal cancer (CRC), revolutionizing the therapeutic landscape and highlighting the indispensable role of the tumor immune microenvironment. However, some CRCs have shown poor response to immunotherapy, prompting investigation into the underlying reasons. It has been discovered that certain chemotherapeutic agents possess immune-stimulatory properties, including the induction of immunogenic cell death (ICD), the generation and processing of non-mutated neoantigens (NM-neoAgs), and the B cell follicle-driven T cell response. Based on these findings, the concept of inducing chemotherapy has been introduced, and the combination of inducing chemotherapy and immunotherapy has become a standard treatment option for certain cancers. Clinical trials have confirmed the feasibility and safety of this approach in CRC, offering a promising method for improving the efficacy of immunotherapy. Nevertheless, there are still many challenges and difficulties ahead, and further research is required to optimize its use.

【 授权许可】

Unknown   
Copyright © 2023 Yao, Han, Yang, Jin and Lan